Lung cancer with concurrent EGFR mutation and ROS1 rearrangement: a case report and review of the literature

• Main Authors: Zhu YC, Xu CW, Ye XQ, Yin MX, Zhang JX, Du KQ, Zhang ZH, Hu J
• Format: Article
• Language: English
• Published: Dove Medical Press 2016-07-01
• Series: OncoTargets and Therapy
• Subjects: Non-small cell lung cancer; EGFR gene mutation; ROS1 fusion gene
• Online Access: https://www.dovepress.com/lung-cancer-with-concurrent--egfr-mutation-and-ros1-rearrangement-a-ca-peer-reviewed-article-OTT

You-cai Zhu,1,2,* Chun-wei Xu,3,* Xiao-qian Ye,4 Man-xiang Yin,4 Jin-xian Zhang,2 Kai-qi Du,2 Zhi-hao Zhang,2 Jian Hu1 1Department of Thoracic Surgery, The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, 2Department of Thoracic Surgery, Chinese People’s Armed Police Force, Zhejiang Corps Hospital, Jiaxing, Zhejiang, 3Department of Pathology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, 4Department of Pathology, Chinese People’s Armed Police Force, Zhejiang Corps Hospital, Jiaxing, Zhejiang, People’s Republic of China *These authors contributed equally to this work Abstract: ROS1 rearrangement has recently emerged as a new molecular subtype in non-small cell lung cancer, and is predominantly found in lung adenocarcinomas compared with other oncogenes such as EGFR, KRAS, or ALK. Patients who have both mutations are extremely rare. Here we report a 50-year-old female diagnosed with adenocarcinoma with sarcomatoid differentiation, who was shown to have EGFR and ROS1 mutations. The patient was treated surgically and received three cycles of adjuvant postoperative chemotherapy. In addition, we reviewed the previously reported cases and related literature. This presentation will provide further understanding of the underlying molecular biology and optimal treatment for non-small cell lung cancer patients with more than one driver mutation. Keywords: non-small cell lung cancer, EGFR gene mutation, ROS1 fusion gene